Share This Link

Gastrointestinal toxicity and hepatotoxicity are not common adverse effects of rituximab, a monoclonal antibody that is used to treat nonHodgkin's lymphoma. Gastrointestinal toxicity and hepatotoxicity may be caused by other drugs, such as methotrexate and cyclophosphamide, which are often used in combination with rituximab. The nurse should monitor the client's liver function tests, such as serum bilirubin, alkaline phosphatase, and transaminases, and report any abnormalities to the provider.

Hypertension and bleeding are not common adverse effects of rituximab, a monoclonal antibody that is used to treat nonHodgkin's lymphoma. Hypertension and bleeding may be caused by other factors, such as renal impairment, coagulation disorders, or anticoagulant therapy. The nurse should monitor the client's blood pressure, urine output, creatinine clearance, coagulation studies, platelet count, and signs of bleeding.

Flulike symptoms and bone marrow suppression are not common adverse effects of rituximab, a monoclonal antibody that is used to treat nonHodgkin's lymphoma. Flulike symptoms and bone marrow suppression may be caused by other drugs, such as interferon alfa and vinblastine, which are also used to treat nonHodgkin's lymphoma. The nurse should monitor the client's temperature, white blood cell count, hemoglobin level, and symptoms of infection or anemia.

Binding to specific antigens on cancer cells and triggering their destruction is the mechanism of action of monoclonal antibodies, such as rituximab and trastuzumab, that are used to treat some types of cancer, such as nonHodgkin's lymphoma and breast cancer. Monoclonal antibodies are proteins that recognize and attach to specific antigens on the surface of cancer cells and activate the immune system to destroy them.

Inhibiting the activity of enzymes that mediate cell growth and survival signals is the mechanism of action of tyrosine kinase inhibitors, such as erlotinib and imatinib, that are used to treat some types of cancer, such as lung cancer and chronic myeloid leukemia. Tyrosine kinase inhibitors are drugs that block the activity of enzymes called tyrosine kinases, which are involved in transmitting signals from growth factors and hormones to the cell nucleus.

Enhancing the immune system's ability to recognize and eliminate cancer cells is the mechanism of action of immunotherapy, such as interferon alfa and interleukin2, that are used to treat some types of cancer, such as melanoma and renal cell carcinoma. Immunotherapy is a type of treatment that uses substances produced by the body or made in a laboratory to boost or restore the immune system's function. Immunotherapy can stimulate the immune system to attack cancer cells or make them more visible to the immune system.

These are not normal side effects of interferon alfa2b, but symptoms of flulike syndrome, which is a common and potentially serious adverse effect of interferon alfa2b, an immunomodulator that enhances the immune system's ability to recognize and eliminate cancer cells. Interferon alfa2b is used to treat melanoma, a type of skin cancer that develops from melanocytes. Flulike syndrome can cause fever, chills, fatigue, myalgia, headache, and malaise. These symptoms may not go away after a few days, but may persist or worsen during the course of treatment.

These are not signs of an allergic reaction to interferon alfa2b, but symptoms of flulike syndrome caused by interferon alfa2b. An allergic reaction to interferon alfa2b would manifest as rash, urticaria, pruritus, angioedema, or anaphylaxis. The client should not stop taking interferon alfa2b without consulting the provider, as this may compromise the effectiveness of the treatment.

These are not indications of bone marrow suppression caused by interferon alfa2b, but symptoms of flulike syndrome caused by interferon alfa2b. Bone marrow suppression is another possible adverse effect of interferon alfa2b, which can result in leukopenia, anemia, and thrombocytopenia. Bone marrow suppression can cause symptoms such as infection, bleeding, or pallor. The client should have their blood counts monitored regularly and receive supportive care as needed.

Cardiotoxicity and extravasation injury are not common adverse effects of nivolumab, a checkpoint inhibitor that blocks the programmed cell death1 (PD1) receptor and enhances the immune system's ability to recognize and eliminate cancer cells. Nivolumab is used to treat renal cell carcinoma, a type of kidney cancer that originates from the renal tubules. Cardiotoxicity and extravasation injury may be caused by other drugs, such as anthracyclines and vinca alkaloids, which are used to treat other types of cancer.

Peripheral neuropathy and pulmonary fibrosis are not common adverse effects of nivolumab, a checkpoint inhibitor that is used to treat renal cell carcinoma. Peripheral neuropathy and pulmonary fibrosis may be caused by other drugs, such as natural products and antineoplastic antibiotics, which are used to treat other types of cancer.

Thrombosis and teratogenicity are not common adverse effects of nivolumab, a checkpoint inhibitor that is used to treat renal cell carcinoma. Thrombosis and teratogenicity may be caused by other factors, such as coagulation disorders, genetic mutations, or pregnancy. The client should have their coagulation studies monitored regularly and receive anticoagulant therapy as prescribed to prevent thrombosis. The client should also avoid pregnancy while receiving nivolumab and use effective contraception methods.